Randomized Trial of Osteoporosis Intervention Strategies in Hip Fracture Patients
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Osteoporosis
- Sponsor
- University of Alberta
- Enrollment
- 220
- Locations
- 1
- Primary Endpoint
- The proportion of patients taking bisphosphonate therapy within 6 months of hip fracture
- Status
- Completed
- Last Updated
- 19 years ago
Overview
Brief Summary
Patients with hip fractures have suffered the most devastating consequence of osteoporosis; and yet, they are rarely if ever tested or treated for the condition, even though they remain at high risk of recurrent fracture.
We hypothesize that, compared with usual care, an allied health professional-run osteoporosis service (case management) will be able to increase testing and treatment of osteoporosis in patients at high risk of fracture.
Detailed Description
Patients with hip fractures have suffered the most devastating consequence of osteoporosis; and yet, they are rarely if ever tested or treated for the condition, even though they remain at high risk of recurrent fracture. We hypothesize that, compared with usual care, an allied health professional-run osteoporosis service (case management) will be able to increase testing and treatment of osteoporosis in patients at high risk of fracture.
Investigators
Eligibility Criteria
Inclusion Criteria
- •hip fracture patient \> 50 years of age
- •able to give consent (or proxy consent available)
- •lives within health region
- •no contraindications to bisphosphonate therapy
Exclusion Criteria
- •refuses to participate or consent
- •dementia or delirium without a proxy consent available
- •nursing home or longterm care
- •pathologic fracture
- •chronic glucocorticoid use
- •already receiving prescription osteoporosis treatment (calcium and vitamin D do not preclude inclusion)
Outcomes
Primary Outcomes
The proportion of patients taking bisphosphonate therapy within 6 months of hip fracture
Secondary Outcomes
- Proportion of patients taking prescription osteoporosis treatment at 6 months and 12 months
- Proportion in receipt of a BMD test at 6 months and 12 months
- Proportion still adherent to osteoporosis treatments at 6 months and 12 months
- Proportion of patients with recurrent fractures at 6 months and 12 months
- Cost effectiveness analyses